Company news
Coherus Oncology, Inc. news in 2023
Coherus Oncology, Inc.'s news releases, calls and decks from 2023, newest first.
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 25, 2023
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 10, 2023
Coherus BioSciences Announces CFO Transition Plans
December 6, 2023
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
December 5, 2023
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
November 5, 2023
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 2, 2023
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
October 29, 2023
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
October 26, 2023
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 13, 2023
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
October 4, 2023
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
October 3, 2023
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 26, 2023
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
September 24, 2023
Coherus Completes Surface Oncology Acquisition
September 7, 2023
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
August 1, 2023
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
July 25, 2023
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
July 19, 2023
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 12, 2023
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
July 2, 2023
Coherus to Acquire Surface Oncology
June 15, 2023
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 4, 2023
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
May 31, 2023
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
May 21, 2023
Coherus Prices Public Offering of Common Stock
May 15, 2023
Coherus Announces Proposed Public Offering of Common Stock
May 14, 2023
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
May 7, 2023
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
April 30, 2023
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
FDA Approves UDENYCA® Autoinjector
March 5, 2023
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
March 5, 2023
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 27, 2023
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 14, 2023
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
February 12, 2023
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
January 8, 2023